Chronic myeloid leukaemia Second and Third line initial PBS authority application Supporting information form (PB122)

You must lodge this form for a patient starting second or third line initial PBS subsidised treatment with a tyrosine kinase inhibitor (TKI agent) for any phase of chronic myeloid leukaemia and who has failed an adequate trial of a first or second-line TKI agent treatment.


Page last updated: 13 July 2016

This information was printed Wednesday 28 September 2016 from It may not include all of the relevant information on this topic. Please consider any relevant site notices at when using this material.